Latest Publications
Artugen Therapeutics R&D VP Laurent Chesnel to Speak at Inaugural Microbiome Leaders Conference
March 18, 2021 Artugen Therapeutics R&D VP Laurent Chesnel to Speak at Inaugural Microbiome Leaders Conference Held Virtually on March 24 Artugen Therapeutics, Ltd., a Company that mines the [...]
Artugen is currently enrolling in C. difficile infection study.
Artugen is currently enrolling subjects in “A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study of ART24 in Subjects Recently Cured of a C. difficile infection” We are looking for volunteers to participate in [...]
Artugen Announces Five Abstracts Published in the 30th ECCMID Abstract Book
The European Congress of Clinical Microbiology and Infectious Diseases happens from 18–21 April in Paris
Artugen Therapeutics Announces First Patient Dosed with ART24
March 12, 2020 Artugen’s first clinical product candidate for prevention of recurrence of Clostridium difficile infection - ART24 granted Fast Track Designation - First Patient Dosed
NIH: “Probiotic bacteria block harmful microbe”
NIAID Director Dr. Anthony S. Fauci talks about the use of bacteria as drugs.
CDC: 2019 AR Threats Report
A newly published CDC report includes the latest national death and infection estimates that underscore the continued threat of CDI in the U.S.